Galsky MD - Search Results

1

What Is the Significance of Variant Histology in Urothelial Carcinoma?

Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA 3rd, Roupret M, Kamat AM. Lobo N, et al. Among authors: galsky md. Eur Urol Focus. 2020 Jul 15;6(4):653-663. doi: 10.1016/j.euf.2019.09.003. Epub 2019 Sep 15. Eur Urol Focus. 2020. PMID: 31530497 Review.

2

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Galsky MD, et al. Invest New Drugs. 2007 Jun;25(3):265-70. doi: 10.1007/s10637-006-9020-9. Epub 2006 Dec 5. Invest New Drugs. 2007. PMID: 17146733 Clinical Trial.

3

Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.

Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF. Galsky MD, et al. Urology. 2007 Feb;69(2):255-9. doi: 10.1016/j.urology.2006.10.029. Urology. 2007. PMID: 17320659 Clinical Trial.

4

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. Galsky MD, et al. Lancet Oncol. 2011 Mar;12(3):211-4. doi: 10.1016/S1470-2045(10)70275-8. Lancet Oncol. 2011. PMID: 21376284 No abstract available.

5

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Galsky MD, et al. Ann Oncol. 2012 Feb;23(2):406-10. doi: 10.1093/annonc/mdr156. Epub 2011 May 4. Ann Oncol. 2012. PMID: 21543626 Free article.

6

Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.

Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Galsky MD, et al. Clin Genitourin Cancer. 2011 Sep;9(1):27-30. doi: 10.1016/j.clgc.2011.05.003. Epub 2011 Jun 22. Clin Genitourin Cancer. 2011. PMID: 21700509

7

Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.

Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y. Svatek RS, et al. Among authors: galsky md. Urol Oncol. 2013 Oct;31(7):968-73. doi: 10.1016/j.urolonc.2011.12.017. Epub 2012 Jan 31. Urol Oncol. 2013. PMID: 22300756 Free PMC article. Review.

8

Novel molecular targets for the therapy of urothelial carcinoma.

Jana BR, Galsky MD, Hahn NM, Milowsky MI, Sonpavde G. Jana BR, et al. Among authors: galsky md. Expert Opin Ther Targets. 2012 May;16(5):499-513. doi: 10.1517/14728222.2012.677441. Epub 2012 Apr 18. Expert Opin Ther Targets. 2012. PMID: 22510032 Review.

9

The emerging role of circulating tumor cell detection in genitourinary cancer.

Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. Small AC, et al. Among authors: galsky md. J Urol. 2012 Jul;188(1):21-6. doi: 10.1016/j.juro.2012.02.2558. Epub 2012 May 12. J Urol. 2012. PMID: 22578722 Review.

10

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.

Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G. Meeks JJ, et al. Among authors: galsky md. Eur Urol. 2012 Sep;62(3):523-33. doi: 10.1016/j.eururo.2012.05.048. Epub 2012 Jun 1. Eur Urol. 2012. PMID: 22677572 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

406 results

Search Page